Thermo Fisher Scientific 透過其 Patheon™ 品牌，提供業界領先的 CDMO（委託開發暨製造）服務，支持製藥與生技公司從藥物開發初期一路到商業化製造的全生命週期。

核心能力涵蓋小分子與大分子開發、生物製劑、細胞與基因療法、mRNA、病毒載體、原料藥（API）生產、劑型開發、臨床試驗物流與商業包裝等。Thermo Fisher 在全球擁有約 60 個據點，配備經驗豐富的科學團隊，提供無縫且整合的服務模式。

最大特色是秉持「策略夥伴」思維，不只是提供服務，更與客戶緊密合作，協助簡化流程、加快時程，並提升治療方案成功上市的機率。
 
Thermo Fisher Scientific 的 Accelerator™ 藥物開發平台 是我們簡化與加速藥物開發的重要里程碑。

這項平台整合 CDMO 與 CRO 功能，成為一套統一且協同的解決方案，協助藥物從早期開發平順過渡到商業化。Accelerator™ 提供法規諮詢、配方開發、臨床試驗包裝與物流、分析服務與可擴展的製造能力，皆由同一個集中化團隊管理。
 
已透過 Accelerator™ 支援超過 100 項全球專案，幫助客戶最多縮短 30% 的時程。此模式對於希望快速推進 IND/IMPD（新藥臨床試驗申請）送件、啟動首度人體試驗，或走加速審查路線的新創與中型生技公司尤其關鍵。
 
商業里程碑包括：全球臨床供應能力的擴展、對先進研發與製造基礎設施的投資，以及啟用可提供即時可視化與專案管理的數位平台。

憑藉約 60 個全球據點，為合作夥伴提供一致的品質、符合法規要求的標準，以及靈活的地理部署能力，支援其全球開發與商業化策略。
 
Accelerator™ 正持續吸引有志簡化流程、降低風險、加速創新療法上市的企業，成為他們值得信賴的整合夥伴。

Thermo Fisher Scientific, through our Patheon™ brand, offers industry-leading CDMO services that support pharmaceutical and biotech companies throughout the drug development lifecycle—from early-stage development to commercial manufacturing.

Our core capabilities span small and large molecule development, biologics, cell and gene therapies, mRNA, viral vectors, API production, formulation, clinical trial logistics, and commercial packaging. With around 60 global sites and a deeply experienced scientific team, we provide a seamless, integrated service model.

What sets us apart is our strategic partnership mindset—we don't just provide services, we collaborate closely with clients to reduce complexity, accelerate timelines, and improve overall success rates in bringing therapies to patients.
 

Thermo Fisher Scientific’s Accelerator™ Drug Development platform is a key milestone in our effort to simplify and accelerate drug development.

By integrating CDMO and CRO capabilities into a single, cohesive solution, Accelerator™ helps streamline the transition from early development to commercialization.

The platform offers regulatory consulting, formulation development, clinical trial packaging and logistics, analytical services, and scalable manufacturing—all managed through one centralized team.
 

We have supported over 100 programs globally through Accelerator™, helping customers reduce timelines by up to 30%.

This model is especially impactful for emerging and mid-sized biopharma companies looking to rapidly achieve IND/IMPD submissions, initiate first-in-human trials, or pursue accelerated regulatory pathways.
 

Our commercial milestones include the global expansion of clinical supply capabilities, investment in advanced development and manufacturing infrastructure, and the launch of digital platforms that enable real-time visibility and project management.

With approximately 60 global sites, we provide our partners with consistent quality, regulatory alignment, and geographic flexibility to support global development and commercialization strategies.Accelerator™ continues to attract companies seeking a unified partner to reduce complexity, mitigate risk, and speed delivery of innovative therapies to patients worldwid.